Anti-PD-1 immunotherapy is emerging as a targeted treatment strategy that has recently shown promise for several aggressive cancers, including melanoma, non-small-cell lung cancer (NSCLC), bladder, and head and neck cancers. This evidence concerns the gene PDCD1 and melanoma.